GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (NAS:PSNL) » Definitions » 3-Year ROIIC %

Personalis (Personalis) 3-Year ROIIC % : -100.82% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Personalis 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Personalis's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -100.82%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Personalis's 3-Year ROIIC % or its related term are showing as below:

PSNL's 3-Year ROIIC % is ranked worse than
83.87% of 217 companies
in the Medical Diagnostics & Research industry
Industry Median: -8.16 vs PSNL: -100.82

Personalis 3-Year ROIIC % Historical Data

The historical data trend for Personalis's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis 3-Year ROIIC % Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial - -399.23 -141.59 -179.08 -100.82

Personalis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -179.08 - - - -100.82

Competitive Comparison of Personalis's 3-Year ROIIC %

For the Diagnostics & Research subindustry, Personalis's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis's 3-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Personalis's 3-Year ROIIC % falls into.



Personalis 3-Year ROIIC % Calculation

Personalis's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -96.3710352 (Dec. 2023) - -42.2050044 (Dec. 2020) )/( 109.774 (Dec. 2023) - 56.05 (Dec. 2020) )
=-54.1660308/53.724
=-100.82%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Personalis  (NAS:PSNL) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Personalis 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Personalis's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (Personalis) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.
Executives
Richard Chen officer: Chief Scientific Officer C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Stephen Michael Moore officer: General Counsel C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Aaron Tachibana officer: Chief Financial Officer 400 NORTH MCCARTHY BLVD, MILPITAS CA 95035
Christopher M Hall officer: President 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Kenneth J Widder director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Lonnie Shoff director C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
John Stephen West director, officer: President and CEO C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Lightspeed Venture Partners Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Olivia Kyusuk Bloom director C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Myers Woodrow A Jr director 1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Ken Ludlum director
Arif Janmohamed other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed Ultimate General Partner Select Iv, L.l.c. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed General Partner Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025